Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 7/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29265250 | 0.86 | DRD2 (0.44) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25405883 | 0.86 | BRD4 (0.43) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL30380364 | 0.86 | DRD2 (0.44) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL29265248 | 0.86 | DRD2 (0.44) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL31376155 | 0.85 | DRD2 (0.43) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL29265249 | 0.85 | BRD4 (0.42) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL29265374 | 0.82 | DRD2 (0.42) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL29265377 | 0.80 | ESR1 (0.34) | TDP1ALDH1A1 | |
| SCHEMBL29265242 | 0.78 | ALDH1A1 (0.47) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25407920 | 0.76 | TDP1 (0.45) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342318-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | RAYZEBIO, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-4380937-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118176194-A | Conjugates comprising covalent binding agents for targeting intracellular proteins | 瑞择生物公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023014988-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | RAYZEBIO, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342318-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | CD2BP2, TP53, CAB39 | TDP1 2872/4885CA12 1634/4885CA1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.